Novartis | NOVN - Gross Profit On Sales

Stock Price
130.50
Daily Change
2.40 1.87%
Monthly
14.27%
Yearly
33.63%
Q1 Forecast
127.33

Novartis reported $10.82B in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alcon AG USD 1.46B 70M Sep/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Autolus Therapeutics Ltd USD -7.45M 3.93M Sep/2025
Bayer EUR 5.35B 1.02B Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Fresenius EUR 1.51B 214M Dec/2025
Fresenius Medical Care EUR 1.39B 147M Dec/2025
Galapagos EUR -13.57M 74.82M Sep/2025
Genmab DKK 868M 195M Jun/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
GRIFOLS EUR 743.8M 49.13M Jun/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
J&J USD 16.6B 118M Dec/2025
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 3.21B 186M Sep/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Novartis USD 10.82B 694M Sep/2025
Novo Nordisk DKK 64.01B 1.19B Jun/2025
Orion EUR 508.7M 254.5M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Philips EUR 2.29B 377M Dec/2025
Recordati EUR 432.41M 8.56M Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 2.46B 520M Dec/2024